Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Neoplasms 2Head and Neck Neoplasms 2Breast Neoplasms 2Mesothelioma, Malignant 1Esophageal Neoplasms 1

Interventions

pembrolizumab 24Magnetic Resonance Spectroscopy 10Carboplatin 8Nivolumab 7Docetaxel 7Paclitaxel 6Gemcitabine 6Trastuzumab 5Taxes 5Injections 5Fluorouracil 5Fluorodeoxyglucose F18 5Drug Therapy 5Cyclophosphamide 5Cisplatin 5fludarabine 4X-Rays 4Specimen Handling 4Radiotherapy 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Leucovorin 4durvalumab 3atezolizumab 3Surveys and Questionnaires 3Standard of Care 3Irinotecan 3Immunohistochemistry 3Gene Expression Profiling 3Early Intervention, Educational 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Tetrahydrouridine × Thoracic × Clear all
NCT03233724 2023-05-31

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
9 enrolled 14 charts
GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡